The price of a normal drug of diabetes called ampgliflose has been cut. Now its price has remained about tenth as compared to before. This change came when many companies launched the generic versions of this drug in the market. Empagliflose was developed by German pharmaceutical company Bohringer Ingelheim (BI) and is sold as Jardians. It is a mouth receiving drug, which helps in controlling blood sugar (blood sugar) of type-2 diabetes patients.
Earlier a bullet was available for so much money
Earlier, a tablet of this medicine was available for about 60 rupees, but now its price has been only Rs 5.5 per pill. This cut was possible when companies like Mankind, Alchem and Glenmark launched its generic versions in the market. Mainkind Pharma has said that its Empagliflogen drug will now be available at a rate of Rs 5.49 per tablet for 10 mg dose and Rs 9.90 per tablet for 25 mg. The company’s vice -president and managing director Rajiv Juneja said, “We are making sure that the price of the drug does not be an obstacle in treatment anymore.”
Arrangements to protect against fake medicines
Alchem company has launched this drug under the name “Emponom”, which has been priced about 80 percent less than the original medicine. The company said that a special safety band has been installed on this drug packet to protect against fake medicines. Also, to make the patients aware, information related to diabetes management in Hindi and English language has been given with pictures. Apart from this, a QR code has also been given, from which additional information related to diabetes, heart disease and kidney disease can be obtained in 11 languages.
How will patients get relief?
Mumbai -based Glenmark Pharmaceuticals have also launched a generic version of Empagliflogen as “Glamampa”. In addition, it has also launched drugs with its mixed diet called “Glampa-L” (ampagliflose + linagliptin) and “Glampa-M” (Empaglogen + Metformin). Alok Malik, president of Glenmark Pharma, said, “This new drug of Glampa category will give an option of affordable and effective treatment to patients suffering from type-2 diabetes, which will also improve patients affected by heart disease.” India is called the capital of diabetes, where in 2023, according to a study by the Indian Council of Medical Research (Diabetes), more than 100 million people were found to be suffering from the disease. In such a situation, reducing the price of diabetes drugs can be an important step towards reducing the increasing burden of this disease.
Disclaimer: Here information provided here is based only on beliefs and information. It is important to mention here that Abplive.com does not confirm any kind of recognition, information. Before implementing any information or recognition, consult the concerned expert.
Also read: Diabetes patients happy! Sugar medicine can be cheaper than 10 rupees, know when
Check out Below Health Tools-
Calculate your body mass index (BMI)
